Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal regulators.

A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S.

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...

On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...